

For Immediate Release
May 28, 2008

Contact: Paul Simon, Vice President of Development, 616.464.5064



Dr. John Landis Joins Board of Directors of Metabolic Solutions Development Co.

Kalamazoo, Mich. – John Landis, Ph.D., has been named to the board of directors of Metabolic Solutions Development Company. Landis is the senior vice president of pharmaceutical sciences at Schering-Plough. He has 30 years of experience in pharmaceutical research and development.

“John has been involved in the development of about 40 drugs that are on the market right now,” said Mark Olesnavage, chairman and chief executive officer of Metabolic Solutions Development Company. “His expertise will be valuable to us at Metabolic Solutions as we develop innovative new therapeutics for treating diabetes.”

Landis joined Schering-Plough in 2003. He leads the global functions of pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, clinical supplies and devices. Before that, he led the global preclinical organization at Pharmacia Corporation (previously Pharmacia & Upjohn). In both organizations, he chaired the development group responsible for governance of all oncology and infectious disease drug development, lifecycle management and licensing activities.

Given the promise of Metabolic Solutions’ ongoing research and development, Landis is hopeful of a positive outcome. “The [company’s central] hypothesis is an interesting one. There haven’t been many new developments in diabetes treatments in the last 25 years and, if this is the answer, that would be very exciting,” said Landis.

Having spent 22 years in Kalamazoo, Mich. with Pharmacia and its predecessors (Pharmacia & Upjohn and The Upjohn Company), Landis is pleased to work with a Michigan-based company again. “It’s good to see economic development that taps into the expertise of the state’s scientific community,” said Landis. “This role gives me the opportunity to give back to the community where I spent so much of my career.”

Landis earned his MS and Ph.D. degrees in analytical chemistry from Purdue University and, earlier this month, received an honorary doctorate of science degree from the institution. He has received several professional awards, including Pharmacia’s Chairman and CEO Award in 2002 and the Distinguished Alumni Award from Purdue University’s School of Science in 1994. He is a member of numerous professional organizations as well as the science advisory board for Southwest Michigan First.

Landis joins Olesnavage; Jerry Callahan, Ph.D.; Jerry Colca, Ph.D.; and Rolf Kletzien, Ph.D.; on Metabolic Solutions’ board of directors.

###

Metabolic Solutions Development Company (www.msdrx.com) is developing innovative therapeutics for the treatment of type 2 diabetes and other metabolic disorders. The company follows a new pharmacological path in the pursuit of low side-effect therapies for diseases in the metabolic syndrome. Formed in January 2006, Metabolic Solutions Development Company is based in Kalamazoo, Mich.